60/100BGE HealthCare Technologies stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for GE HealthCare Technologies is 81.14, 1.5% below the current price of 82.39. Their targets range from 67.00 to 95.00.
Of the 16 firms that rated GE HealthCare Technologies in the past 12 months, 10 rate it buy or strong buy, 6 hold and 0 sell or strong sell (each firm at its latest rating): a Buy consensus.
Analysts' 1-year price targets range from 67.00 to 95.00, with an average of 81.14.
| Buy | 10 | |
| Hold | 6 | |
| Sell | 0 |
12-month price target
| Highest target | 95.00 |
| Average target | 81.14 |
| Lowest target | 67.00 |
| Current price | 82.39 |
GE HealthCare Technologies price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their GE HealthCare Technologies price target and rating?
How analysts rate GE HealthCare Technologies, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
10 of 16 firms rate it buy now, against 6 of 9 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
GE HealthCare Technologies analyst upgrades, downgrades and price targets
The latest rating change came on 21 May 2026, when UBS upgraded GE HealthCare Technologies from Sell to Neutral. Its price target is 69.00, from 77.00. The most recent new target came from Barclays on 29 October 2026: 95.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 29 Oct 2026 | Barclays Christopher Pasquale | Reiterated · Overweight | 85.00 → 95.00 | +11.8% | 75.82 |
| 6 Oct 2026 | Barclays | — | 78.00 → 85.00 | +9.0% | 64.77 |
| 22 Sept 2026 | Needham | — | 93.00 | — | 64.81 |
| 30 Jul 2026 | Evercore ISI | Reiterated · Outperform | 80.00 → 84.00 | +5.0% | 69.06 |
| 29 Jul 2026 | BTIG | Reiterated · Buy | 75.00 → 79.00 | +5.3% | 71.54 |
| 16 Jul 2026 | UBS | Reiterated · Neutral | 69.00 → 67.00 | -2.9% | 64.23 |
| 13 Jul 2026 | BTIG Ryan Zimmerman | — | 91.00 → 75.00 | -17.6% | 64.70 |
| 8 Jul 2026 | BMO Capital | — | 70.00 | — | 64.68 |
| 23 Jun 2026 | RBC Capital | — | 80.00 | — | 60.64 |
| 21 May 2026 | UBS Graham Doyle | Upgraded · Sell → Neutral | 77.00 → 69.00 | -10.4% | 64.26 |
| 30 Apr 2026 | Evercore ISI | Reiterated · Outperform | 95.00 → 80.00 | -15.8% | 59.81 |
| 30 Apr 2026 | Oppenheimer Suraj Kalia | — | 85.00 | — | 60.04 |
| 30 Apr 2026 | Barclays Matt Miksic | Reiterated · Equal Weight | 87.00 → 78.00 | -10.3% | 59.49 |
| 30 Apr 2026 | Goldman Sachs David Roman | Downgraded · Buy → Neutral | 98.00 → 65.00 | -33.7% | 59.49 |
| 29 Apr 2026 | Stifel Nicolaus | — | 98.00 → 80.00 | -18.4% | 60.06 |
| 17 Apr 2026 | Piper Sandler | Reiterated · Overweight | 94.00 → 88.00 | -6.4% | 73.20 |
| 13 Apr 2026 | Mizuho Securities | Reiterated · Outperform | 90.00 | — | 72.69 |
| 6 Feb 2026 | Barclays | Reiterated · Equal Weight | 86.00 → 87.00 | +1.2% | 82.31 |
| 4 Feb 2026 | Stifel Nicolaus Rick Wise | — | 95.00 → 98.00 | +3.2% | 82.63 |
| 4 Feb 2026 | Morgan Stanley | — | 74.00 → 85.00 | +14.9% | 82.63 |
| 4 Feb 2026 | BTIG Ryan Zimmerman | Reiterated · Buy | 87.00 → 91.00 | +4.6% | 83.70 |
| 30 Jan 2026 | Piper Sandler | Reiterated · Overweight | 94.00 | — | 78.78 |
| 15 Jan 2026 | UBS | Downgraded · Neutral → Sell | 73.00 → 77.00 | +5.5% | 85.30 |
| 9 Jan 2026 | Goldman Sachs | — | 98.00 | — | 88.16 |
| 7 Jan 2026 | Stifel Nicolaus | Reiterated · Buy | 90.00 → 95.00 | +5.6% | 86.73 |
| 5 Jan 2026 | Evercore ISI | — | 95.00 | — | 84.20 |
| 11 Dec 2025 | Jefferies | Reiterated · Buy | 105.00 | — | 85.54 |
| 21 Nov 2025 | Stifel Nicolaus Rick Wise | — | 90.00 | — | 76.29 |
GE HealthCare Technologies EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect GE HealthCare Technologies's EPS to grow 10.4% a year until 2028, faster than over the last 5 years (0.6% a year) and the last 3 years (2.5%).
Analysts expect GE HealthCare Technologies's revenue to grow 5.3% a year until 2028, about as fast as over the last 5 years (3.7% a year) and the last 3 years (4.0%).
Revenue
EPS
Does GE HealthCare Technologies beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 7.7% off the result, either way, and their revenue estimate 1.5%, over the last 12 quarters.
- EPS beats
- 13 / 15
- Revenue beats
- 11 / 15
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +6.8%
- Since
- April 2023
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 28 Oct 2026 | 1.20 | 1.34 | +11.7% | 5.35B | 5.51B | +3.0% |
| Q2 FY2026 | 29 Jul 2026 | 1.04 | 1.13 | +8.7% | 5.26B | 5.30B | +0.6% |
| Q1 FY2026 | 29 Apr 2026 | 1.04 | 0.99 | -4.8% | 5.04B | 5.13B | +1.8% |
| Q4 FY2025 | 4 Feb 2026 | 1.40 | 1.44 | +2.9% | 5.61B | 5.70B | +1.5% |
| Q3 FY2025 | 29 Oct 2025 | 1.05 | 1.07 | +1.9% | 5.09B | 5.14B | +1.1% |
| Q2 FY2025 | 30 Jul 2025 | 0.92 | 1.06 | +15.5% | 4.97B | 5.01B | +0.7% |
| Q1 FY2025 | 30 Apr 2025 | 0.91 | 1.01 | +10.5% | 4.66B | 4.78B | +2.5% |
| Q4 FY2024 | 13 Feb 2025 | 1.26 | 1.45 | +15.1% | 5.33B | 5.32B | -0.2% |
| Q3 FY2024 | 30 Oct 2024 | 1.05 | 1.14 | +8.6% | 4.87B | 4.86B | -0.1% |
| Q2 FY2024 | 31 Jul 2024 | 0.98 | 1.00 | +2.0% | 4.88B | 4.84B | -0.8% |
| Q1 FY2024 | 30 Apr 2024 | 0.91 | 0.90 | -1.1% | 4.80B | 4.65B | -3.2% |
| Q4 FY2023 | 6 Feb 2024 | 1.07 | 1.18 | +10.3% | 5.09B | 5.21B | +2.2% |
GE HealthCare Technologies stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If GE HealthCare Technologies's earnings keep growing at the 10.2% a year analysts expect to FY2028, it would earn about 7.44 a share in FY2030. At the P/E it has traded at over the last five years (12.2 to 25.4) that is 91.08 to 189.19 a share, or 134.80 at its average P/E of 18.1. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 5.02 | 61.43 | 90.92 | 127.61 |
| FY2027 | 5.52 | 67.57 | 100.01 | 140.36 |
| FY2028 | 6.13 | 75.02 | 111.03 | 155.83 |
| FY2029 (extrapolated) | 6.75 | 82.66 | 122.34 | 171.70 |
| FY2030 (extrapolated) | 7.44 | 91.08 | 134.80 | 189.19 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 10.2% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (12.2, 18.1, 25.4).
Is GE HealthCare Technologies stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
GE HealthCare Technologies's P/E of 21.3 is above the middle of its 5-year range (13.1 to 30.8, median 19.8). Analysts expect faster growth than in recent years, which can explain part of the high P/E. Buyers pay less for each point of growth than usual: a PEG of 2.0 on expected growth against 31.6 on its median P/E and past five years' growth. At its usual P/E (19.8 × EPS of 3.86), GE HealthCare Technologies's fair value is 76.47; the price, 82.39, is 7.7% above it. Its forward P/E, on the consensus for FY2026, is 16.4.
Fair value is the usual (median) P/E of the last five years times the earnings per share of the last twelve months; the ends of the bar are the same earnings at its lowest and highest P/E of those years (13.1 and 30.8). The price against its P/E range
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 21.34
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 19.81
- Five-year P/E range
- 13.1 – 30.8
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 16.42
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 2.10
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- -1.5%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 99.090 | 194.93146Price 99.09244 | +96.7% | |
| 42.225 | 82.9546Price 42.23165 | +96.4% | |
| 186.680 | 360.82271Price 186.68451 | +93.3% | |
| 213.670 | 405.57304Price 213.67507 | +89.8% | |
| 161.160 | 305.51157Price 161.16396 | +89.6% | |
| 160.650 | 300.09225Price 160.65375 | +86.8% | |
| 165.860 | 308.95212Price 165.86442 | +86.3% |
Furthest below the fair value on each stock's page, updated every day.